New EU-funded Doctoral Network to sensitise critical multidrug-resistant bacteria to antibiotics
An alarming number of infections have become hard or impossible to treat. As more and more bacteria and viruses grow resistant to antimicrobial medicines, antimicrobial resistance is considered one of today’s greatest health threats facing humanity.[i] With innovation in the development of new antibiotics lacking, other solutions are urgently needed. A new EU-funded research and training programme, BREAKthrough, approaches the problem from a different angle: it aims to develop a new compound that will modify bacteria in a way that makes them vulnerable to existing antibiotics.
Drug-resistant diseases are causing at least 700,000 deaths every year. It is estimated that by 2050, this number may have risen to 10 million if no action is taken.[ii] Among the drug-resistant microbes, one of the most critical threats is posed by multidrug-resistant bacteria, so-called “superbugs”, which have been a major cause of infections in the past years and are spreading rapidly. Due to various barriers impeding the development of new antibiotics,[iii] no new antibiotic classes have been discovered in the past 35 years, further increasing the urgency of the problem.
A promising solution: breaking through superbugs’ protective shell
BREAKthrough, a new Europe-wide Doctoral Network funded within the Marie Skłodowska-Curie Actions (MSCA) framework, will take on the most notorious type of superbug, Gram-negative bacteria, whose cell envelope (“walls”) prevent antibiotics from entering. The research aims to damage the cell envelope so that it no longer forms an obstacle and enables antibiotics to pass through and kill the bacterial cell. To develop novel compounds that can do this, BREAKthrough brings together experts from both academia and industry, covering fields like bacterial genetics, biophysics, cell biology, organic chemistry, pharmaceutical chemistry, and biochemistry. The project’s outcomes will have a significant scientific and societal impact: not only will the new compounds open up new avenues for developing new antibiotics, but they can also form new effective treatments through synergy with already existing antibiotics.
Being part of the BREAKthrough Doctoral Network, the project partners will recruit and train eleven doctoral candidates (DCs). The DCs will benefit from the international, intersectoral, and interdisciplinary nature of the BREAKthrough network through secondments at partner organisations. Acquiring an extensive set of scientific, business, and transferrable skills through the training programme, the DCs will be well-equipped to become the next generation of scientists in drug development with entrepreneurial flair and a good understanding of the challenges of drug development in an industrial context. The BREAKthrough DC job advertisements can be found on the project website and on the European Commission’s EURAXESS portal.